NOV 08, 2022 2:15 PM PST

Blood Pressure Drug May Reduce Alzheimer's Risk in Black People

WRITTEN BY: Annie Lennon

Telmisartan, a blood pressure-lowering medication, may help prevent or treat Alzheimer's disease (AD) in Black individuals. The corresponding study was published in Alzheimer's' and Dementia

AD is the most common form of dementia, making up around 60-70% of dementia cases. According to Alzheimer's Association, 6.5 million Americans aged 65 and older have AD. Few medications have been approved for AD, and those that have often provide modest benefits in symptom management and do not halt or slow disease progression.

In the US, older African American adults are at a 1.5-2 fold higher risk for developing AD compared to older non-Hispanic American adults of European origin. Previous studies have also found that African American individuals are at a higher risk of high blood pressure than non-Hispanic European individuals. Meanwhile, studies show that antihypertensive medications can lower the risk of mild cognitive impairment.

In the current study, researchers analyzed health data from 5.62 million insured US individuals aged 60 and over to investigate the link between antihypertensive medications and AD. 

In doing so, they noted that moderate to high use of an antihypertensive drug, telmisartan, was linked to lower incidence of AD in African Americans- but not those of non-Hispanic European descent. Telmisartan works by blocking angiotensin II, a hormone that causes blood vessels to constrict.

"Considering race-specific drug responses holds potential for drastically improving patient care," Feixiong Cheng, Ph.D., of Cleveland Clinic Genomic Medicine Institute, and corresponding author of the study, said in a press release, "Identifying these candidate drugs can also reveal more information about the disease itself through referencing the medicine's targets."

The researchers noted that their findings warrant randomized controlled trials with ethnically diverse patient cohorts. Such research, they hope, could establish causality and therapeutic outcomes for telmisartan and AD. 

 

Sources: Alzheimer's' and Dementia, Neuroscience News

 

About the Author
Other
Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
NOV 16, 2022
Drug Discovery & Development
Flavonoid Delivery Using Nanoparticles Currently On Route
Flavonoid Delivery Using Nanoparticles Currently On Route
In their article, Dewanjee et al. explains how the use of nanoparticles is a novel solution that can specifically addres ...
NOV 28, 2022
Neuroscience
Modified 'Bath Salts' Hold Potential to Treat Depression
Modified 'Bath Salts' Hold Potential to Treat Depression
Experimental synthetic drugs may treat depression and anxiety-related disorders with few adverse side effects. The corre ...
DEC 01, 2022
Cannabis Sciences
Study Finds CBD Does Not Reduce the Psychoactive High Caused by THC
Study Finds CBD Does Not Reduce the Psychoactive High Caused by THC
Researchers from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London found ...
DEC 04, 2022
Cannabis Sciences
Increasing Interest in Psychoactive Treatments for Mood Disorders
Increasing Interest in Psychoactive Treatments for Mood Disorders
Findings from various studies presented at the Society for Neuroscience 2022 annual meeting highlighted the need for inn ...
DEC 30, 2022
Health & Medicine
Individuals in Mid-Adulthood Sleep Less Than Younger and Older Adults
Individuals in Mid-Adulthood Sleep Less Than Younger and Older Adults
A study published in Nature Communications found that people sleep less on average in mid-adulthood than in early and la ...
JAN 19, 2023
Drug Discovery & Development
Introducing TruCytes™: The Ready-to-Use Immunophenotyping Control for Cell Therapy, Flow Cytometry and Beyond
Introducing TruCytes™: The Ready-to-Use Immunophenotyping Control for Cell Therapy, Flow Cytometry and Beyond
Are you a cell biologist, immunologist, or flow cytometrist? If so, you know how challenging it is to find quality contr ...
Loading Comments...